It has happened again. The last of the great Expedition studios, the third of the series to be exact, has failed. After the news of a couple of years ago, I think we all feared it. Solanezumab (finished in “-mab” for “monoclonal antibody”) does not significantly decrease the cognitive impairment associated with Alzheimer’s disease. It was a Phase III. With more than 2,000 patients. The largest study done to date on the modulation of amyloid in Alzheimer’s disease.

See original (not translated) news ➥

 

See translated news ➥